Sign in
Taking people in United StatesPhase 4

Comparing two antipsychotic medicines for psychosis in Lewy body disease

Compares pimavanserin and quetiapine for hallucinations and delusions in Parkinson's or Lewy body dementia.

Key facts

Who runs it
The University of Texas Health Science Center at San Antonio
Where
San Antonio, United StatesSee the 2 sites
Trial code
Registry title
Comparing Antipsychotic Medications in LBD Over Time
Status
Recruiting
Phase
Phase 4
People taking part
94 people, planned
Started
22 Apr 2022
Expected to end
Feb 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Pimavanserin
  • Quetiapine
Record updated
9 September 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with hallucinations or delusions caused by Parkinson's disease or dementia with Lewy bodies who need to start an antipsychotic medicine. It compares pimavanserin and quetiapine.

Sex
All sexes can join.
Disease stage
Psychosis (hallucinations and/or delusions) due to Parkinson's disease (PD) or dementia with Lewy bodies (DLB).
Earlier treatment
Must need to start an antipsychotic medicine. People currently taking an antipsychotic cannot join.

Main reasons for not taking part

  • A medical reason why either medicine cannot be used
  • No caregiver available to complete the NPI-Q
  • Currently taking an antipsychotic medicine
  • The prescribing provider is unwilling to manage either medicine

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Patients seen in the neurology clinic at UT Health San Antonio
  • Diagnosed with psychosis due to PD or DLB
  • Requiring initiation of an antipsychotic medication
  • Clinical equipoise between quetiapine and pimavanserin must exist
  • The prescribing provider must be comfortable prescribing and managing both quetiapine and pimavanserin

Who cannot take part

  • Medical contraindication to either medication
  • Currently taking an antipsychotic medication
  • Prescribing provider unwilling to manage either medication
  • Caregiver unavailable to complete NPI-Q

Where in United States

  • University Health SystemSan Antonio, United StatesContact: Sarah Horn, MDTaking people
  • UT Health Science Center San AntonioSan Antonio, United StatesContact: Carolyn PaizTaking people

About the trial

What the trial wants to find out

The primary objective of this study is to determine whether treatment with pimavanserin or quetiapine is associated with a greater improvement in psychosis when used in a routine clinical setting to treat hallucinations and/or delusions due to Parkinson's disease (PD) or dementia with Lewy bodies (DLB) - collectively referred to as Lewy body disease (LBD).

The 2 groups in the trial

  • quetiapineExisting treatment, for comparison

    Elderly patients with dementia-related psychosis will be treated with quetiapine, an atypical antipsychotic indicated for the treeatment of: schizophrenia, bipolar I manic episodes and bipolar depressive episodes.

  • pimavanserinExisting treatment, for comparison

    Elderly patients with dementia-related psychosis will be treated with pimavanserin, an atypical antipsychotic indicated for treatment of hallucinations and delusions associated with Parkinson's disease.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Pragmatic Randomized Trial Comparing Antipsychotics in Lewy Body Disease
Plain-language title
Comparing two antipsychotic medicines for psychosis in Lewy body diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
9 September 2025